Compare DexCom, Inc. (DXCM) vs Kraft Heinz Co (KHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Kraft Heinz Co — how do they compare? DexCom, Inc. trades at $78.49 (market cap $28.06B), while Kraft Heinz Co trades at $25.88 (market cap $30.18B). The key difference: DexCom, Inc. and Kraft Heinz Co are close in size by market cap, and Kraft Heinz Co pays a 6.29% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | KHC | |
|---|---|---|
Market Cap | $28.06B | $30.18B |
Sector | Health | Consumer Staples |
52-Week High | $89.53 | $28.94 |
52-Week Low | $54.84 | $21.21 |
Enterprise Value | $27.03B | $47.22B |
Dividend Yield | — | 6.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Kraft Heinz (KHC) trades at $25.08, down 0.59% on the day, with a bullish technical signal supported by moving averages. The company has beaten earnings expectations for three consecutive quarters, though it reported a net loss of $5.85B in 2025. Valuation metrics show a low P/B ratio of 0.72, while the company maintains strong operating cash flow of $4.46B and recently announced a global restructuring to accelerate growth.
KHC presents a mixed investment case with attractive valuation and dividend yield (6.4%) offset by profitability challenges. The stock trades above analyst consensus target of $23.20, suggesting limited near-term upside. Key risks include persistent negative margins and high debt levels, while potential catalysts include successful restructuring execution and margin improvement in upcoming quarters.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →
